Uterine Fibroid Treatment: An Evolving Medical Technology

 

Overview:

Therapeutic embolization (PE) is an effective Uterine Fibroid Treatment. It is performed under local anesthesia, so the patient remains conscious but sedated. They feel very little pain during the procedure. A small incision is made in the groin, where the interventional radiologist inserts a tiny catheter. These catheters carry a small substance called polyvinyl alcohol into the arteries surrounding the fibroid. Once inside the uterus, the small spheres occlude the blood supply, resulting in the fibroids shrinking over weeks.

To Get Complete Industry Insights, Grab Sample PDF Copy Here: https://bit.ly/3JY8W4E

Market Drivers:

Rise in cases of uterine fibroids in women around the globe is expected to augment growth of the global uterine fibroid treatment market over the forecast period. As per the research published in the journal ResearchGate in September 2021, nearly 25% of women and up to 30 to 40% of women aged 40 years and above involved in the study had clinical symptoms of uterine fibroid. 

Moreover, increasing preference of patients towards minimally invasive procedures and growing initiatives taken for boosting the awareness regarding early diagnosis and treatment of fibroid is also expected to boost growth of the global uterine fibroid treatment market over the forecast period. 

Market Restraints:

Factors such as high cost and healthcare reforms taken by government are likely to hamper growth of the global uterine fibroid treatment market over the forecast period. 

Regional Insights:

North America among other regions is anticipated to witness substantial growth in the global uterine fibroid treatment market over the forecast period due to growing cases of uterine fibroids and rise in number of surgeries in countries such as Canada and the U.S. in the region.

Asia Pacific is also anticipated to witness strong growth in the global uterine fibroid treatment market over the forecast period. This is due to presence of large pool of patients, and unmet requirements about diagnosis and treatment of fibroids across the region. 

Key Players:

Major players functioning in the global uterine fibroid treatment market are Richard Wolf GmbH, Blue Endo, Olympus Corporation, Boston Scientific Corporation, Merit Medical Systems, CooperSurgical, Inc., LiNA Medical USA, KARL STORZ SE & Co. KG, Halt Medical, Inc., and Myovant Sciences (Sumitovant Biopharma Ltd.)

In May 2021, the U.S. Food and Drug Administration (FDA) granted approval to Myivant Sciences and Pfizer for their MYFEMBREE, a first once-daily treatment for heavy menstrual bleeding related with uterine fibroids.